<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mosley, Mary</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Natale, Andrea</style></author><author><style face="normal" font="default" size="100%">Di Biase, Luigi</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Uninterrupted Anticoagulation With Catheter Ablation Feasible and Effective</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-07-02 10:57:42</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">7-8</style></pages><abstract><style  face="normal" font="default" size="100%">In patients with nonvalvular atrial fibrillation who are undergoing catheter ablation, VENTURE AF has shown that uninterrupted rivaroxaban compared with uninterrupted warfarin is associated with a risk of periprocedural thromboembolic events and major bleeding that was similar to that seen with warfarin. An open-label multicenter registry with uninterrupted apixaban vs uninterrupted warfarin yielded the same result.</style></abstract><number><style face="normal" font="default" size="100%">12</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>